Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

What will Eli Lilly do with all its cash from Mounjaro and Zepbound? What does CEO Dave Ricks think it would take for the company to reach a $1 trillion market capitalization? And how does Ricks ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...